<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T03:55:20Z</responseDate>
  <request identifier="oai:figshare.com:article/34053378" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34053378</identifier>
        <datestamp>2026-10-02T04:36:21Z</datestamp>
        <setSpec>category_388</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Table 1_Stage IA undifferentiated uterine sarcoma with SMARCA4 and SMARCA2 co-deficiency: a case report.docx</dc:title>
          <dc:creator>Rong Ji (1496803)</dc:creator>
          <dc:creator>Xialin Chen (11861460)</dc:creator>
          <dc:creator>Juan Lang (17022510)</dc:creator>
          <dc:creator>Zhongkui Xiong (24300518)</dc:creator>
          <dc:subject>Oncology and Carcinogenesis not elsewhere classified</dc:subject>
          <dc:subject>co-deficiency</dc:subject>
          <dc:subject>disease-free survival</dc:subject>
          <dc:subject>SMARCA2</dc:subject>
          <dc:subject>SMARCA4</dc:subject>
          <dc:subject>undifferentiated uterine sarcoma</dc:subject>
          <dc:description>&lt;p&gt;Uterine sarcomas represent a rare and heterogeneous group of malignancies whose management remains clinically challenging. They account for approximately 3%–5% of all uterine malignancies. Undifferentiated uterine sarcoma (UUS) is a subtype of uterine sarcomas. SMARCA4 is a tumor suppressor gene that is aberrantly altered in approximately 5%–7% of human malignancies. SMARCA4-deficient UUS is a highly aggressive, undifferentiated mesenchymal neoplasm associated with a median overall survival (OS) of 7 months. During tumorigenesis, loss of function of either SMARCA4 or SMARCA2 is frequently observed; however, concurrent loss of both genes has been reported to be synthetically lethal and is therefore considered unexpected. In this case report, a 52-year-old Chinese woman with early-stage UUS and SMARCA4 and SMARCA2 co-deficiency underwent surgical resection followed by adjuvant chemotherapy and achieved a disease-free survival (DFS) of 32 months. This case suggests that patients with UUS harboring SMARCA4 and SMARCA2 co-deficiency may derive a survival benefit from early diagnosis and surgical resection. However, owing to the extreme rarity of UUS with co-deficiency of SMARCA4 and SMARCA2, conducting a high-level phase III randomized controlled trial to validate this observation remains impractical.&lt;/p&gt;</dc:description>
          <dc:date>2026-10-02T04:36:21Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fonc.2026.1939651.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Table_1_Stage_IA_undifferentiated_uterine_sarcoma_with_SMARCA4_and_SMARCA2_co-deficiency_a_case_report_docx/34053378</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
